САЩ - английски - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - dicloxacillin sodium (unii: 4hzt2v9kx0) (dicloxacillin - unii:cof19h7wbk) - to reduce the development of drug-resistant bacteria and maintain the effectiveness of dicloxacillin sodium capsules and other antibacterial drugs, dicloxacillin sodium capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. dicloxacillin is indicated in the treatment of infections caused by penicillinase-producing staphylococci which have demonstrated susceptibility to the drug. cultures and susceptibility tests should be performed initially to determine the causative organisms and their sensitivity to the drug (see clinical pharmacology – susceptibility  testing ) . dicloxacillin may be used to initiate therapy in suspected cases of resistant stap

САЩ - английски - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - dicloxacillin sodium (unii: 4hzt2v9kx0) (dicloxacillin - unii:cof19h7wbk) - to reduce the development of drug-resistant bacteria and maintain the effectiveness of dicloxacillin sodium capsules and other antibacterial drugs, dicloxacillin sodium capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. dicloxacillin is indicated in the treatment of infections caused by penicillinase-producing staphylococci which have demonstrated susceptibility to the drug. cultures and susceptibility tests should be performed initially to determine the causative organisms and their sensitivity to the drug (see clinical pharmacology – susceptibility  testing ) . dicloxacillin may be used to initiate therapy in suspected cases of resistant stap

САЩ - английски - NLM (National Library of Medicine)

asclemed usa, inc. - dicloxacillin sodium (unii: 4hzt2v9kx0) (dicloxacillin - unii:cof19h7wbk) - to reduce the development of drug-resistant bacteria and maintain the effectiveness of dicloxacillin sodium capsules and other antibacterial drugs, dicloxacillin sodium capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. dicloxacillin is indicated in the treatment of infections caused by penicillinase-producing staphylococci which have demonstrated susceptibility to the drug. cultures and susceptibility tests should be performed initially to determine the causative organisms and their sensitivity to the drug (see clinical pharmacology – susceptibility plate testing ) . dicloxacillin may be used to initiate therapy in suspected cases of resistant

САЩ - английски - NLM (National Library of Medicine)

aurobindo pharma limited - dicloxacillin sodium (unii: 4hzt2v9kx0) (dicloxacillin - unii:cof19h7wbk) - to reduce the development of drug-resistant bacteria and maintain the effectiveness of dicloxacillin sodium capsules and other antibacterial drugs, dicloxacillin sodium capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. dicloxacillin sodium capsules are indicated in the treatment of infections caused by penicillinase-producing staphylococci which have demonstrated susceptibility to the drug. cultures and susceptibility tests should be performed initially to determine the causative organisms and their sensitivity to the drug (see clinical pharmacology – susceptibility testing ). dicloxacillin sodium capsules may be used to initiate therapy in suspected cases of resistant staphylococcal infections prior to the availability of laboratory test results. the penicillinase-resistant penicillins should not be used in infections caused by organisms susceptible to penicillin g. if the susceptibility tests indicate that the infection is due to an organism other than a resistant staphylococcus, therapy should not be continued with a penicillinase-resistant penicillin. dicloxacillin sodium capsules are contraindicated in persons who have shown hypersensitivity to any of the penicillins or any component of the formulations.

САЩ - английски - NLM (National Library of Medicine)

avera mckennan hospital - dicloxacillin sodium (unii: 4hzt2v9kx0) (dicloxacillin - unii:cof19h7wbk) - dicloxacillin 250 mg

САЩ - английски - NLM (National Library of Medicine)

lake erie medical & surgical supply dba quality care products llc - dicloxacillin sodium (unii: 4hzt2v9kx0) (dicloxacillin - unii:cof19h7wbk) - dicloxacillin 500 mg

САЩ - английски - NLM (National Library of Medicine)

avera mckennan hospital - dicloxacillin sodium (unii: 4hzt2v9kx0) (dicloxacillin - unii:cof19h7wbk) - dicloxacillin 500 mg

Австралия - английски - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - flucloxacillin, quantity: 1 g - injection, powder for - excipient ingredients: - treatment of confirmed or suspected staphylococcal infections and other gram-positive coccal infections including pneumonia, skin and skin structure and wound infections, infected burns and cellulitis.

Австралия - английски - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - flucloxacillin, quantity: 500 mg - injection, powder for - excipient ingredients: - treatment of confirmed or suspected staphylococcal infections and other gram-positive coccal infections including pneumonia, skin and skin structure and wound infections, infected burns and cellulitis.

Малта - английски - Malta Medicines Authority

panpharma z.i. du clairay, 35133 luitre, france - flucloxacillin - powder for solution for infusion or injection - flucloxacillin 500 mg - antibacterials for systemic use